Defining actionable mutations for oncology therapeutic development

Nature Reviews Cancer 16, 319 (2016).
doi:10.1038/nrc.2016.35

Authors: T. Hedley Carr, Robert McEwen, Brian Dougherty, Justin H. Johnson, Jonathan R. Dry, Zhongwu Lai, Zara Ghazoui, Naomi M. Laing, Darren R. Hodgson, Francisco Cruzalegui, Simon J. Hollingsworth & J. Carl Barrett
Genomic profiling of tumours in patients in clinical trials enables rapid testing of multiple hypotheses to confirm which genomic events determine likely responder groups for targeted agents. A key challenge of this new capability is defining which specific genomic events should be classified as 'actionable'

Source: Nature Reviews Cancer - April 25, 2016 Category: Cancer & Oncology Authors: T. Hedley CarrRobert McEwenBrian DoughertyJustin H. JohnsonJonathan R. DryZhongwu LaiZara GhazouiNaomi M. LaingDarren R. HodgsonFrancisco CruzaleguiSimon J. HollingsworthJ. Carl Barrett Tags: Perspectives Source Type: research